Dr. Cho speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about a phase I/II trial of lazertinib(GNS-1480, YH25448), a highly selective and irreversible investigational 3rd-generation EGFR-TKI.
Genosco's pipeline GNS-1480 (YH25448) was presented at ASCO 2018. *ASCO stands for American Society of Clinical Oncology Annual Meeting.
ASCO 2018 Poster Board: #356 • Abstract 9033; Byoung Chul Cho - First Author, Severence Hospital
Business Wire * May 16, 2018; Abstract - https://meetinglibrary.asco.org/record/161036/abstract
Genosco's pipeline GNS-1480 (YH25448) was presented at AACR Annual meeting 2018. *AACR stands for American Association for Cancer Research.
This article was published on Cancer Research - AACR Journals, doi: 10.1158/0008-5472.CAN-16-2432 in February 2017.
Genosco's pipeline GNS-1480 (Yuhan code: YH25448) was presented at the IASLC 17th World Conference on Lung Cancer in December 2016. *IASLC stands for International Association for the Study of Lung Cancer.
This article was published in The FEBS Journal, Volume 238, Issue 19, Pages 3613-3625 in October 2016.
This article was published in Bioorganic & Medicinal Chemistry Letters, Volume 25, Issue 20, Pages 4441-4446 in October 2015. It was also featured in World Biomedical Frontiers.
